Immuneering (IMRX) Current Assets (2020 - 2026)

Immuneering's Current Assets history runs 7 years deep, the most recent figure standing at $161.4 million for Q1 2026.

• On a quarterly basis, Current Assets rose 322.47% year-over-year to $161.4 million in Q1 2026; TTM through Mar 2026 was $161.4 million, a 322.47% increase from a year earlier, with the FY2025 full-year figure at $176.2 million, up 345.21% from the prior year.
• Current Assets retreated to $161.4 million in Q1 2026 per IMRX's latest filing, from $176.2 million in the prior quarter.
• Across five years, Current Assets topped out at $229.1 million in Q3 2025 and bottomed at $27.7 million in Q2 2025.
• The 5-year median for Current Assets is $100.6 million (2023), against an average of $103.4 million.
• Biggest YoY gain for Current Assets was 345.21% in 2025; the steepest drop was 56.47% in 2025.
• Year by year, Current Assets stood at $108.7 million in 2022, then fell by 18.08% to $89.1 million in 2023, then plunged by 55.56% to $39.6 million in 2024, then soared by 345.21% to $176.2 million in 2025, then dropped by 8.42% to $161.4 million in 2026.
• Per Business Quant, the three latest IMRX Current Assets figures stand at $161.4 million (Q1 2026), $176.2 million (Q4 2025), and $229.1 million (Q3 2025).